kidney cancer

February 27, 2024

Multi-institutional study of Wilms tumor facilitates enrollment, optimizes treatment

Multi-institutional study finds that enrollment and outcomes were similar across racial and ethnic groups for children participating in therapeutic trials for Wilms tumor — the most common pediatric kidney cancer worldwide.

By Leigh MacMillan
October 31, 2023

VUMC’s Kimryn Rathmell wins Doris Duke Foundation Paragon Award

Kimryn Rathmell, MD, PhD, chair of Medicine at Vanderbilt University Medical Center, has received the Paragon Award for Research Excellence from the Doris Duke Foundation.

By Bill Snyder
Frank Mason, PhD, left, Kimryn Rathmell, MD, PhD, and their colleagues have identified an early event in the development of cancer, one that could lead to new ways to prevent it. (photo by Erin O. Smith)
September 20, 2023

VUMC study reveals critical first steps to cancer

A new study by Vanderbilt researchers provides a remarkably detailed view of the earliest events leading to the development of cancer, and of potential new ways to prevent it.

By Bill Snyder
February 17, 2022

Grant to support Haake’s research on kidney cancer

Kure It Cancer Research has awarded a $200,000 grant to support kidney cancer research by Vanderbilt’s Scott Haake, MD.

By Tom Wilemon
May 24, 2021

Analysis reveals macrophages associated with kidney cancer recurrence

A white blood cell, the TREM2/APOE/C1Q-positive macrophage, has been identified as a potential biomarker to predict recurrence of the most common type of kidney cancer and as a possible target for drug development.

By Tom Wilemon
April 6, 2021

Genetic differences in Wilms tumor

Unique somatic gene mutations may contribute to racial disparities in the incidence of Wilms tumor — the most common childhood kidney cancer.

By Leigh MacMillan
November 10, 2020

Study underscores importance of personalized medicine in kidney cancer

A new study sheds light on how molecular subsets within the tumors of kidney cancer patients determine treatment outcomes and underscores the importance of personalized medicine in making therapy decisions.
By Tom Wilemon
November 6, 2019

Rathmell receives 2019 Eugene P. Schonfeld Award

The Kidney Cancer Association is recognizing the research accomplishments and leadership achievements of W. Kimryn Rathmell, MD, PhD, with its top honor, the Eugene P. Schonfeld Award.
By Tom Wilemon
October 24, 2019

Urologic cancer expert Rini joins VICC as chief of Clinical Trials

Brian Rini, MD, an internationally recognized leader in genitourinary oncology, kidney cancer, and clinical drug development, is joining Vanderbilt-Ingram Cancer Center as the inaugural chief of Clinical Trials.
By Tom Wilemon
February 28, 2019

Achilles’ heel for kidney cancer

The discovery that kidney cells with mutations in a certain gene are sensitive to therapies called PI3K inhibitors opens new opportunities for applying precision medicine to cancer treatment.
By VUMC News and Communications
May 10, 2018

Grant bolsters kidney cancer immunotherapy research

W. Kimryn Rathmell, MD, PhD, Cornelius Abernathy Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center (VICC), has received a grant to research the role of immunosuppression in the tumor microenvironment for kidney cancer.
By Doug Campbell
August 17, 2017

Kidney cancer patient, survivor event set for Sept. 9

Vanderbilt-Ingram Cancer Center (VICC) will sponsor an educational conference for kidney cancer patients, survivors and family members Saturday, Sept. 9, 8 a.m. – 2 p.m., in the Preston Research Building, Suite 898.
By VUMC News and Communications
September 2, 2016

Kidney cancer educational conference at VICC set Sept. 10

Kidney cancer patients, family members, health care providers and members of the public are invited to attend a free educational workshop about the disease to be held at Vanderbilt-Ingram Cancer Center (VICC).
By VUMC News and Communications
1 2